Variants in isocitrate dehydrogenase (IDH) genes are observed in around 20% of patients diagnosed with AML (~7% for IDH1), and clinical outcomes are known to differ due to co-occurrence of other mutations, IDH subtypes, treatment strategies, and patient factors [16–21]. Here, IDH1 is linked to acute myeloid leukemia.